Eupraxia Pharmaceuticals Closes $80.5 Million Public Offering

Eupraxia Pharmaceuticals ( (TSE:EPRX) ) has provided an update.

On September 24, 2025, Eupraxia Pharmaceuticals Inc. announced the successful closing of its public offering, raising approximately $80.5 million through the sale of 14,636,363 common shares. The proceeds are intended to support the advancement of its product pipeline, including ongoing clinical trials and regulatory activities, as well as research and development initiatives and corporate growth strategies.

The most recent analyst rating on (TSE:EPRX) stock is a Buy with a C$12.00 price target. To see the full list of analyst forecasts on Eupraxia Pharmaceuticals stock, see the TSE:EPRX Stock Forecast page.

Spark’s Take on TSE:EPRX Stock

According to Spark, TipRanks’ AI Analyst, TSE:EPRX is a Neutral.

Eupraxia Pharmaceuticals’ overall score reflects its challenging financial position with no revenue and ongoing net losses. While recent positive trial results and operational progress are encouraging, the company’s reliance on external financing and high liabilities pose significant risks. Technical indicators suggest some positive momentum, but valuation challenges persist due to lack of profitability. The strengthened financial position through capital raise is a mitigating factor but does not offset the underlying financial instability.

To see Spark’s full report on TSE:EPRX stock, click here.

More about Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals Inc. operates in the pharmaceutical industry, focusing on the development of innovative drug products. The company is engaged in advancing its product pipeline, which includes preclinical studies and clinical trials, as well as regulatory submissions and manufacturing scale-up activities.

Average Trading Volume: 37,821

Technical Sentiment Signal: Buy

Current Market Cap: C$291.8M

For detailed information about EPRX stock, go to TipRanks’ Stock Analysis page.